Overview

Tecemotide (L-BLP25) in Prostate Cancer

Status:
Completed
Trial end date:
2016-11-25
Target enrollment:
Participant gender:
Summary
This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
EMD Serono
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Goserelin